Zacks Investment Research Upgrades TherapeuticsMD Inc (TXMD) to Hold
TherapeuticsMD Inc (NASDAQ:TXMD) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Thursday.
According to Zacks, “TherapeuticsMD, Inc. is a specialty pharmaceutical company focused on creating branded prescription, generic prescription and over-the-counter products targeted exclusively for women. It is developing three advanced hormone replacement products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. TherapeuticsMD, Inc. is based in Boca Raton, Florida. “
Other research analysts have also recently issued reports about the company. Jefferies Group reaffirmed a “buy” rating on shares of TherapeuticsMD in a research report on Wednesday, June 8th. Noble Financial reissued a “buy” rating and set a $17.50 price objective on shares of TherapeuticsMD in a report on Monday, July 11th.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/zacks-investment-research-upgrades-therapeuticsmd-inc-txmd-to-hold.html
TherapeuticsMD (NASDAQ:TXMD) opened at 6.32 on Thursday. The stock’s 50 day moving average is $7.02 and its 200 day moving average is $7.65. The company’s market cap is $1.24 billion. TherapeuticsMD has a 52-week low of $5.18 and a 52-week high of $11.26.
TherapeuticsMD (NASDAQ:TXMD) last issued its earnings results on Thursday, August 4th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.10) by $0.01. The company earned $4.40 million during the quarter, compared to analysts’ expectations of $5.63 million. TherapeuticsMD’s revenue for the quarter was down 8.3% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.16) earnings per share. Equities research analysts forecast that TherapeuticsMD will post ($0.43) earnings per share for the current year.
TherapeuticsMD, Inc is a women’s healthcare product company. The Company’s segment is creating and commercializing products for women. It is focused on conducting clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products. Its drug candidates are created using its SYMBODA hormone technology, which enables the administration of hormones with high bioavailability alone or in combination.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with MarketBeat.com's FREE daily email newsletter.